Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- Status
- TERMINATED
- Phase
- PHASE4
Clinical Trials Related to Relapsing Multiple Sclerosis
Related studies linked through entity extraction aliases.
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
- Status
- WITHDRAWN
- Phase
- PHASE4
Natalizumab Subcutaneous Immunogenicity and Safety Study
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
- Status
- COMPLETED
- Phase
- PHASE3
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients
- Status
- COMPLETED
- Phase
- N/A
An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device
- Status
- COMPLETED
- Phase
- N/A
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Status
- COMPLETED
- Phase
- PHASE3
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
- Status
- WITHDRAWN
- Phase
- PHASE2
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Status
- COMPLETED
- Phase
- PHASE3
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
- Status
- COMPLETED
- Phase
- PHASE3
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
- Status
- COMPLETED
- Phase
- PHASE3
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
- Status
- COMPLETED
- Phase
- N/A
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
- Status
- TERMINATED
- Phase
- PHASE3
The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial
- Status
- COMPLETED
- Phase
- PHASE4
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
- Status
- COMPLETED
- Phase
- PHASE2
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
- Status
- TERMINATED
- Phase
- PHASE3
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
- Status
- COMPLETED
- Phase
- PHASE3